Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZW191 · 1 trial · 1 indication
Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to ZW191
Number of participants who experienced AEs, adverse events of special interest (AESIs), or serious adverse events (SAEs)
Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0
Number of participants who achieved a best overall response of either confirmed complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
| Arm | Type | Description |
|---|---|---|
| ZW191 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZW191 | DRUG | Administered intravenously |
Inclusion Criteria: * Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease. * Measurable disease per RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. * Adequat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ZW191 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in a clinical trial enrolling participants with advanced solid tumors.
ZW191 targets folate receptor alpha (FR⍺), a protein that is often overexpressed in certain types of cancer cells. By targeting FR⍺, ZW191 aims to deliver its therapeutic effect specifically to tumor cells that express this receptor, potentially reducing damage to healthy cells.
ZW191 is being developed by Zymeworks Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol ZYME. The company is conducting clinical trials to evaluate the safety and efficacy of ZW191 in patients with advanced solid tumors.
ZW191 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities such as the FDA. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
ZW191 is being studied in a Phase 1 clinical trial with the identifier NCT06555744, titled 'A Study of ZW191 in Participants With Solid Tumors.' This trial is actively recruiting participants and has an estimated enrollment of 145 patients. The study is being conducted in the United States, Australia, Japan, Singapore, South Korea, and Spain.
ZW191 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials. However, it has received Fast Track designation from the FDA, which is a process designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.